Effect of levetiracetam on depression and anxiety in adult epileptic patients

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 2, 2008, Pages 539-543

  Mazza, Marianna ^a   Martini, Annalisa ^a   Scoppetta, Marta ^a   Mazza, Salvatore ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Anxiety; Behavioral problems; Depression; Epilepsy; Levetiracetam

Indexed keywords

CARBAMAZEPINE; ETIRACETAM; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; VALPROATE SEMISODIUM;

ADULT; AGED; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFECT; EPIGASTRIC DISCOMFORT; EPILEPSY; FATIGUE; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; IRRITABILITY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MOOD CHANGE; NAUSEA; PSYCHOMETRY; QUALITY OF LIFE; SIDE EFFECT;

ADULT; AGE FACTORS; ANTICONVULSANTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; DIZZINESS; EPILEPSIES, PARTIAL; FEMALE; HUMANS; MALE; PIRACETAM; PLACEBO EFFECT; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 38749108890     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.10.015     Document Type: Article

References (42)

1. Alsaadi T.M., Koopmans S., Apperson M., and Farias S. Levetiracetam monotherapy for elderly patients with epilepsy. Seizure 13 (2004) 58-60
2. Alsaadi T.M., Shatzel A., Marquez A.V., Jorgensen J., and Farias S. Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study. Seizure 14 (2005) 139-142
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), American Psychiatric Association, Washington, DC
4. Andermann E., Andermann F., Meyvisch P., and Tonner F. Efficacy and tolerability of levetiracetam add-on therapy in patients with refractory idiopathic generalised epilepsy. Epilepsia 47 Suppl.4 (2006) 187
5. Ben-Menachem E., Falter U., and for the European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 41 (2000) 1276-1283
6. Ben-Menachem E., Edrich P., Van Vleymen B., Sander J.W., and Schmidt B. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy. Epilepsy Res 53 (2003) 57-64
7. Besag F.M. Behavioral effects of the newer antiepileptic drugs: an update. Expert Opin Drug Saf 3 (2004) 1-8
8. Betts T., Waegemans T., and Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 9 (2000) 80-87
9. Braunig P., and Kruger S. Levetiracetam in the treatment of rapid cycling bipolar disorder. J Psychopharmacol 17 2 (2003) 239-241
10. Brodie M.J., et al., for the Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 68 6 (2007) 402-408
11. Cramer J.A., De Rue K., Devinsky O., Edrich P., and Trimble M.R. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 4 2 (2003) 124-132
12. Desarkar P., Das B., and Sinha V.K. Adjuvant levetiracetam in adolescent mania. J Clin Psychopharmacol 27 2 (2007) 215-216
13. Ferrendelli J.A., French J., Leppik I., Morrell M.J., Herbeuval A., Han J., et al. Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial. Epilepsy Behav 4 (2003) 702-709
14. Gaitatzis A., Trimble M.R., and Sander J.W. The psychiatric comorbidity of epilepsy. Acta Neurol Scand 110 4 (2004) 207-220
15. Gilliam F.G., Mendiratta A., Pack A.M., and Brazil C.W. Epilepsy and common comorbidities: improving the outpatient epilepsy encounter. Epileptic Disord 7 1 (2005) 27-33
16. Glauser T.A., et al., on behalf of the N159 Study Group. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 66 (2006) 1654-1660
17. Goldberg J.F., and Burdick K.E. Levetiracetam for acute mania. Am J Psychiatry 159 (2002) 1
18. Gomer B., Wagner K., Frings L., Saar J., Carius A., Harle M., et al. The influence of antiepileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav 10 3 (2007) 486-494
19. Harden C. Safety profile of levetiracetam. Epilepsia 42 suppl 4 (2001) 36-39
20. Jain K.K. An assessment of levetiracetam as an anti-epileptic drug. Expert Opin Investig Drugs 9 (2000) 1611-1624
21. Kalogjera Sackellares D., and Sackellares J.C. Improvement in depression associated with partial epilepsy in patients treated with lamotrigine. Epilepsy Behav 3 (2002) 510-516
22. Kanner A.M. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol Psychiatry 54 (2003) 388-398
23. Kaufman K.R. Monotherapy treatment of bipolar disorder with levetiracetam. Epilepsy Behav 5 6 (2004) 1017-1020
24. Kinrys G., Wygant L.E., Pardo T.B., and Melo M. Levetiracetam for treatment-refractory posttraumatic stress disorder. J Clin Psychiatry 67 2 (2006) 211-214
25. Lagae L., Buyse G., and Ceulemans B. Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial. Epilepsia 14 (2005) 66-71
26. Lukyanetz E.A., Shkryl V.M., and Kostyuk P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 43 1 (2002) 9-18
27. Lynch B.A., Lambeng N., Nocka K., Kensel-Hammes P., Bajjalieh S.M., Matagne A., et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101 26 (2004) 9861-9866
28. Margineau D.G., and Klitgaard H. Levetiracetam. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs. 5th Edition (2002), Lippincott Williams & Wilkins, Philadelphia
29. Mazza M., Di Nicola M., Della Marca G., Janiri L., Bria P., and Mazza S. Bipolar disorder and epilepsy: a bidirectional relation? Neurobiological underpinnings, current hypotheses, and future research directions. Neuroscientist 13 4 (2007) 392-404
30. Mazza M., Della Marca G., Di Nicola M., Martinotti G., Pozzi G., Janiri L., et al. Oxcarbazepine improves mood in epileptic patients. Epilepsy Behav 10 3 (2007) 397-401
31. Muralidharan A., and Bhagwagar Z. Potential of levetiracetam in mood disorders: a preliminary review. CNS Drugs 20 12 (2006) 969-979
32. Otoul C., Arrigo C., van Rijckevorsel K., and French J.A. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 28 (2005) 72-78
33. Paciello N., Mazza M., and Mazza S. Depression in epilepsy: symptom or syndrome?. Clin Ter 153 6 (2002) 397-402
34. Papp L.A. Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. J Clin Psychiatry 67 10 (2006) 1573-1576
35. Seethalakshmi R., and Krishnamoorty E.S. Depression in epilepsy: phenomenology, diagnosis and management. Epileptic Disord 9 1 (2007) 1-10
36. Shorvon S.D., and van Rijckevorsel K. Levetiracetam, a pyrrolidone recently licensed as an antiepileptic drug. J Neurol Neurosurg Psychiatry 72 (2002) 426-428
37. Simon N.M., Worthington J.J., and Doyle A.C. An open-label study of levetiracetam for the treatment of social anxiety disorder. J Clin Psychiatry 65 (2004) 1219-1222
38. Stoner S.C., Lea J.W., Wolf A.L., and Berges A.A. Levetiracetam for mood stabilization and maintenance of seizure control following multiple treatment failures. Ann Pharmacother 39 11 (2005) 1928-1931
39. Verdru P., Wajgt A., Schiemann Delgado J., and Noachtar S. Efficacy and safety of levetiracetam 3000 mg/d as adjunctive treatment in adolescents and adults suffering from idiopathic generalised epilepsy with myoclonic seizures. Epilepsia 46 Suppl.6 (2005) 56
40. Walden J., Langosch J., Born C., Schaub G., and Grunze H. Levetiracetam and ethosuximide in the treatment of acute mania in an open study with an on-off-on design. Bipolar Disord 4 1 (2002) 114
41. White J.R., WalczaK T.S., Leppik I.E., Rarick J., Tran T., Beniak T.E., et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology 61 (2003) 1218-1221
42. Zhang W., Connor K.M., and Davidson J.R. Levetiracetam in social phobia: a placebo controlled pilot study. J Psychopharmacol 10 5 (2005) 551-553